Erenumab (Aimovig) vs Zavegepant (Zavzpret)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Erenumab (Aimovig)

Marketed by Amgen and partners

Approved in Migrainemonoclonal antibody
Reliable signal

NCT02456740 · Phase 3 · completed

The trial randomly assigned 955 participants to erenumab 70 mg, erenumab 140 mg, or placebo and used quadruple blinding during the 24-week placebo-controlled phase. The clinical primary endpoint, change in monthly migraine days, was significantly better with both erenumab doses than with placebo.

Next expected readout: July 2031 · NCT07655440 (registry estimate)

Reported efficacy

Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) (met)

Result source: NCT03867201

Zavegepant (Zavzpret)

Marketed by Pfizer

Approved in Migrainesmall molecule
Reliable signal

NCT04571060 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial, with 623 zavegepant-treated and 646 placebo-treated participants included in the efficacy analysis. Both prespecified primary clinical endpoints were met: pain freedom and freedom from the most bothersome symptom at 2 hours were significantly higher with zavegepant than placebo.

Next expected readout: March 2027 · NCT06401642 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Zavegepant (Zavzpret): registry results are on file for Migraine, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Erenumab (Aimovig)
Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) NCT02456740 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine days (last 4 of 12 weeks): erenumab 70 mg -6.64 and 140 mg -6.63 vs placebo -4.18; differences -2.46 (95% CI -3.52 to -1.39) and -2.45 (95% CI -3.51 to -1.38), both p<0.001 (CT.gov posted results). NCT02066415 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase): Placebo -1.84 migraine days / month (Standard Error 0.21) | Erenumab 70 mg QM -2.88 migraine days / month (Standard Error 0.21) NCT02483585 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) NCT03867201 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Erenumab (Aimovig)'s landscape · Zavegepant (Zavzpret)'s landscape